Mustang Bio Inc (MBIO) Stock Price, Quote & News

Company Profile

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory gl...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Website: www.mustangbio.com

Address:

95 Sawyer Road, Suite 110, Waltham, United States

FinSUN May. 11 at 3:18 PM

$MBIO

1 · Reply

FinSUN May. 8 at 9:36 AM

$FBIO the stock is still 33% higher YoY. Given the governance, the debt, the unresolved dividends payment and the total disaster of many subsidiaries like $MBIO and $ATXI plus the disappointing revenue of $DERM , not to mention the ongoing dilution with B. $RILY as ATM agent, I consider this still overpriced.

1 · Reply

PenkeInvesting May. 7 at 11:04 AM

Fundamental analysis of $MBIO (MUSTANG BIO, INC.) based on financial data and reported results. #MBIO

1 · Reply

justiceforb_85 May. 7 at 3:21 AM

$MBIO will they ever provide a clinical update this year? Or lights out...?

0 · Reply

FinSUN May. 5 at 8:20 PM

$MBIO Mustang Bio Q1 net loss widens to $955,000; operating loss increases to $1.06 million https://www.webullapp.com/news-detail/14831089407255552?__app_cfg__=%7B%22supportTheme%22%3Atrue%7D&sourcePage=QuotesFragment&tickerId=913253379&audioNewsPlayedDuration=&theme=1&color=2&hl=en&android_sdk_int=36&canary-version=&_v=1&sp=1&statusBarHeightV2=26&isLite=false&wbFontSetting=standard&wbFontUnit=19&wbFontSize=19&isSubsNews=false

0 · Reply

czarfast1 Apr. 29 at 7:09 PM

$MBIO tancho??

6 · Reply

FinSUN Apr. 29 at 6:15 PM

$MBIO

0 · Reply

iNVidiousGeek Apr. 26 at 10:14 PM

$MBIO I wish black rock would show this gem some love. For them it is money in the bank.

0 · Reply

SMM82 Apr. 20 at 1:41 PM

$MBIO Delisting notice on Friday… https://ir.mustangbio.com/sec-filings/all-sec-filings

3 · Reply

FinSUN Apr. 10 at 9:29 PM

$MBIO new ATL next week.

2 · Reply

IBN Announces Latest Episode of The TechMediaWire Podcast featuring Justin Hanka, CEO of MindBio Therapeutics Corp.

May 12, 2026, 8:30 AM EDT - 1 day ago

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Leveraging AI, Voice Analysis to Develop Intoxication Detection

2025-07-07T12:35:38.000Z - 11 months ago

Mustang Bio granted orphan drug designation by FDA for MB-101

Jul 7, 2025, 8:30 AM EDT - 11 months ago

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma

2025-07-01T16:25:18.000Z - 11 months ago

Mustang Bio treatment of malignant glioma granted orphan designation

2025-03-05T21:40:52.000Z - 1 year ago

Mustang Bio regains compliance with Nasdaq requirement

Mar 5, 2025, 4:15 PM EST - 1 year ago

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

FBIO

2025-02-27T22:45:21.000Z - 1 year ago

Mustang Bio exits lease for Massachusetts facility, divests equipment

ABBV

Feb 27, 2025, 4:05 PM EST - 1 year ago

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

2025-02-11T21:40:16.000Z - 1 year ago

Mustang Bio regains compliance with Nasdaq

Feb 11, 2025, 4:10 PM EST - 1 year ago

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 10, 2025, 8:00 AM EST - 1 year ago

Mustang Bio Announces Closing of $8 Million Public Offering

2025-02-06T12:27:09.000Z - 1 year ago

Mustang Bio prices 2.66M shares at $3.01 in public offering

Feb 6, 2025, 7:00 AM EST - 1 year ago

Mustang Bio Announces Pricing of $8 Million Public Offering

2025-01-16T00:51:00.000Z - 1 year ago

Mustang Bio trading halted, news pending

2025-01-15T21:20:13.000Z - 1 year ago

Mustang Bio files to sell common stock and warrants, no amount given

2025-01-14T13:26:29.000Z - 1 year ago

Mustang Bio announces 1-for-50 reverse stock split

Jan 14, 2025, 8:00 AM EST - 1 year ago

Mustang Bio Announces Reverse Stock Split

2024-11-22T21:55:07.000Z - 1 year ago

Mustang Bio files to sell 34.77M shares of common stock for holders

2024-11-12T13:35:08.000Z - 1 year ago

Mustang Bio receives positive listing determination from Nasdaq

Nov 12, 2024, 8:30 AM EST - 1 year ago

Mustang Bio Receives Positive Listing Determination from Nasdaq

2024-11-07T13:45:08.000Z - 1 year ago

Mustang Bio granted Orphan Drug Designation by U.S. FDA for MB-108

Nov 7, 2024, 8:30 AM EST - 1 year ago

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Oct 24, 2024, 2:10 PM EDT - 1 year ago

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

2024-10-22T20:21:36.000Z - 1 year ago

Mustang Bio treatment of malignant glioma granted FDA orphan status

2024-09-17T10:10:25.000Z - 1 year ago

Mustang Bio rating placed under review at H.C. Wainwright

2024-07-19T21:28:27.000Z - 1 year ago

Mustang Bio files to sell 6.5M shares of common stock for holders

Jun 28, 2024, 8:00 AM EDT - 2 years ago

Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

ENVB

Jun 21, 2024, 4:01 PM EDT - 2 years ago

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

2024-06-20T15:17:16.000Z - 2 years ago

Biotech Alert: Searches spiking for these stocks today

AVTE BNTX CARA GOSS ITCI MIRM OVID

Jun 20, 2024, 8:00 AM EDT - 2 years ago

Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 18, 2024, 2:52 AM EDT - 2 years ago

Why are Mustang Bio shares (MBIO) up almost 500%?

Jun 17, 2024, 8:30 AM EDT - 2 years ago

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy

May 2, 2024, 4:01 PM EDT - 2 years ago

Mustang Bio Announces Closing of $4 Million Public Offering

Apr 29, 2024, 8:00 PM EDT - 2 years ago

Mustang Bio Announces Pricing of $4 Million Public Offering

Mar 28, 2024, 9:00 AM EDT - 2 years ago

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Mar 11, 2024, 4:05 PM EDT - 2 years ago

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Mar 7, 2024, 7:30 AM EST - 2 years ago

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

Jan 11, 2024, 8:30 AM EST - 2 years ago

Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

Dec 11, 2023, 8:30 AM EST - 2 years ago

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

Nov 14, 2023, 4:05 PM EST - 2 years ago

Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 2, 2023, 9:28 AM EDT - 2 years ago

Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

Oct 30, 2023, 2:15 PM EDT - 2 years ago

Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 26, 2023, 12:30 PM EDT - 2 years ago

Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 26, 2023, 9:00 AM EDT - 2 years ago

Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

Sep 7, 2023, 8:15 AM EDT - 2 years ago

Mustang Bio to Participate in Upcoming September 2023 Investor Conferences

Aug 16, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

Aug 14, 2023, 4:05 PM EDT - 2 years ago

Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Aug 3, 2023, 8:00 AM EDT - 3 years ago

Mustang Bio to Participate in Two August 2023 Investor Conferences

Jul 31, 2023, 8:30 AM EDT - 3 years ago

Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences

Jul 6, 2023, 8:00 AM EDT - 3 years ago

Mustang Bio Announces Participation in Upcoming Scientific Meetings

Jun 15, 2023, 4:01 PM EDT - 3 years ago

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Jun 12, 2023, 8:00 AM EDT - 3 years ago

Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

May 18, 2023, 8:03 AM EDT - 3 years ago

Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates

May 12, 2023, 4:05 PM EDT - 3 years ago

Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

May 11, 2023, 4:03 PM EDT - 3 years ago

Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy

Mar 29, 2023, 4:15 PM EDT - 3 years ago

Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

Mar 28, 2023, 8:30 AM EDT - 3 years ago

Mustang Bio to Participate in Cantor's The Future of Oncology Virtual Symposium

Jan 17, 2023, 8:15 AM EST - 3 years ago

Mustang Bio to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

Dec 19, 2022, 8:30 AM EST - 3 years ago

Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

Nov 14, 2022, 4:05 PM EST - 3 years ago

Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Oct 27, 2022, 8:00 AM EDT - 3 years ago

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia

Oct 6, 2022, 8:30 AM EDT - 3 years ago

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Sep 8, 2022, 8:00 AM EDT - 3 years ago

Mustang Bio to Participate in Upcoming September 2022 Investor Conferences

Aug 11, 2022, 4:05 PM EDT - 4 years ago

Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Jul 27, 2022, 8:00 AM EDT - 4 years ago

Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency

FinSUN May. 11 at 3:18 PM

$MBIO

1 · Reply

FinSUN May. 8 at 9:36 AM

1 · Reply

PenkeInvesting May. 7 at 11:04 AM

Fundamental analysis of $MBIO (MUSTANG BIO, INC.) based on financial data and reported results. #MBIO

1 · Reply

justiceforb_85 May. 7 at 3:21 AM

$MBIO will they ever provide a clinical update this year? Or lights out...?

0 · Reply

FinSUN May. 5 at 8:20 PM

0 · Reply

czarfast1 Apr. 29 at 7:09 PM

$MBIO tancho??

6 · Reply

FinSUN Apr. 29 at 6:15 PM

$MBIO

0 · Reply

iNVidiousGeek Apr. 26 at 10:14 PM

$MBIO I wish black rock would show this gem some love. For them it is money in the bank.

0 · Reply

SMM82 Apr. 20 at 1:41 PM

$MBIO Delisting notice on Friday… https://ir.mustangbio.com/sec-filings/all-sec-filings

3 · Reply

FinSUN Apr. 10 at 9:29 PM

$MBIO new ATL next week.

2 · Reply

rombrento Apr. 1 at 7:51 PM

$MBIO

1 · Reply

FinSUN Mar. 25 at 9:07 PM

$MBIO

1 · Reply

Adolf_Stocktler Mar. 25 at 1:14 PM

$MBIO pos always teasing premarket

0 · Reply

Diiiii Mar. 23 at 1:36 PM

$RILY Digging deeper into this post, and the plot thickens. Asher (via DBA Trading / Intracoastal) isn’t just some random whale. He actually has a deep history with B. Riley Securities. On multiple PIPE and warrant deals, B. Riley acts as the Agent, and Asher is the Purchaser. (Examples: $MBIO, $SIDU, $SQNS). Think about it: A guy who knows B. Riley's core business firsthand through actual deals—and usually sticks to ultra-safe arbitrage—just stepped out of his safety zone to drop a massive, directional bet right before the critical 3/31 10-K deadline. If this doesn't scream bullish conviction, I don't know what does. Truly a fascinating setup.

0 · Reply

SMM82 Mar. 20 at 4:01 PM

$MBIO Back into the beautiful abyss. Looks like their annual report came out the other day for those that may want to do a little digging. Good see the CEO is still collecting ~$500K / year paycheck.

1 · Reply

Adolf_Stocktler Mar. 9 at 2:27 PM

$MBIO heading back to 50 cents again

0 · Reply

JTE_Theta Mar. 5 at 4:12 PM

Disseminated on behalf of MindBio Therapeutics (CSE: $MBIO) (OTCQB: $MBQIF) AI Voice Tech Turning Human Speech Into Real Time Risk Signals 🧬 With 50M+ voice data points, their platform detects cognitive & physiological biomarkers from short voice samples ! No hardware, No wearables, No invasive testing. CommunicatedDisclaimer: http://tinyurl.com/54jmx7k9

1 · Reply

JTE_Theta Mar. 4 at 1:51 AM

🧠The Mental Health Market Is Broken. $MBIO / $MBQIF Is Building Something Different. Traditional antidepressants can take weeks to work, often come with heavy side effects, and don’t help everyone. MindBio Therapeutics Corp is developing regulated, take-home psychedelic microdosing therapies designed for scalable treatment of depression, anxiety, PTSD, and cancer related distress. Their lead program, MB22001, is currently in Phase 2 clinical development -Ttargeting structured protocols that could move psychedelic therapy beyond clinics and into accessible, real world care. Why this is interesting 🧠 • Focus on regulated take home model vs in clinic only treatments • Late stage clinical progress in a rapidly emerging sector • Integration of AI health monitoring tech for data + safety • Exposure to a multi billion dollar global mental health opportunity CommunicatedDisclaimer:http://tinyurl.com/4sahjja4

1 · Reply

BillionerOfKing Feb. 22 at 2:28 PM

$MBIO Current Stock Price: $0.99

0 · Reply

FinSUN Feb. 21 at 9:40 AM

$MBIO let this miserable pos die

0 · Reply

FinSUN Feb. 21 at 9:29 AM

$MBIO Considering Fortress history, both recent and old one, these scammers allmost certainly "work" for B Riley. What else do you expect ? Classy ! 😂😂

0 · Reply

FinSUN Feb. 21 at 9:24 AM

$MBIO typical of a paid shill 🤣🤣 zero financial arguments, 100% personal offenses. Your miserable life means nothing and you know it. Time to find a new job...

0 · Reply

Market Cap	5.00M
Revenue (ttm)	0.00
Net Income (ttm)	-1.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	61,100
Avg Vol	38,288
Day's Range	N/A - N/A
Shares Out	7.58M
Stochastic %K	22%
Beta	2.11
Analysts	Strong Buy
Price Target	$8.00